Want to create an interactive transcript for this episode?
Podcast: PeerView Clinical Pharmacology CME/CNE/CPE Video
Episode: April W. Armstrong, MD, MPH - Understanding TYK2’s Role in Psoriasis Pathogenesis and Taking a Practical Approach to Realizing Its Potential in the Clinic
Description: Go online to PeerView.com/XMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis, a chronic inflammatory disease that affects up to 1 in 20 people worldwide, can drastically impact a patient's quality of life and health. The number of therapies for patients with moderate-to-severe psoriasis has grown steadily over the past 2 decades. Biologic immunotherapies have been the primary agents to gain approval, while small-molecule therapies have lagged in development. Deucravacitinib is a newly approved oral small molecule that inhibits the activity of TYK2, a member of the JAK family. Deucravacitinib allosterically inhibits...